Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108355 · ClinicalTrials.gov registry record · Phase 4
Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
A Phase 4 study of Cirrhosis and Ascites, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00108355: Completed Phase 4 study of Cirrhosis and Ascites, sponsored by US Department of Veterans Affairs.
NCT00108355 is a Phase 4 study of Cirrhosis and Ascites that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 29 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00108355, a Phase 4 study of Cirrhosis and Ascites, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites.
Primary Outcome
Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group)
Interventions
- DRUG Midodrine
- DRUG Octreotide LAR
- DRUG Albumin
- DRUG Intravenous Saline Infusion (Albumin placebo)
- DRUG Oral tablet (Midodrine placebo)
Study Locations (1)
Connecticut
- VA Connecticut Health Care System (West Haven) - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2003-12 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
What the finished NCT00108355 record still lists
NCT00108355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 5 interventions - of which Midodrine is the first listed.
NCT00108355 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00108355 about?
NCT00108355 is a clinical study titled "Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis". This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites.
What is the current status of trial NCT00108355?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2003-12. Estimated completion is 2012-08.
What conditions does trial NCT00108355 study?
This clinical trial studies the following conditions: Cirrhosis, Ascites.
What interventions are being tested in trial NCT00108355?
The interventions under investigation include: Midodrine (DRUG), Octreotide LAR (DRUG), Albumin (DRUG), Intravenous Saline Infusion (Albumin placebo) (DRUG), Oral tablet (Midodrine placebo) (DRUG).
Who is sponsoring clinical trial NCT00108355?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00108355 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00108355's enrollment target sits among peer trials
29 42nd of 53 higher than 12 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ramelteon for Treatment of Insomnia in Cirrhosis
COMPLETED · Phase 4
-
The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
COMPLETED · Phase 4
-
Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting
RECRUITING
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia